
Exploring Novel Treatment Developments in Radiation Oncology
Although 2 theranostics medicines are FDA-approved for prostate and neuroendocrine tumors, the growing utility of these therapies may expand as more patients are eligible for these treatments, according to Brandon Mancini, MD, MBA, FACRO. CancerNetwork® …